ARTICLES BY THE NCJDRSU SINCE 1990
(updated September 2016)

2016


2015


2014


2013


2012


2011


2010


123. Will B. Variant CJD: where has it gone, or has it? Practical Neurology 2010; 10:250-251.

2009


2008


2007


2006


204. Cooper SA, Murray KL, Heath CA, Will RG, Knight RSG. Sporadic Creutzfeldt-Jakob disease with cerebellar ataxia at onset in the United Kingdom. JNNP 2006; 77:1273-1275.


220. St Rose SG, Hunter N, Matthews L, Foster JD, Chase-Topping ME, Kruuk LE, Shaw DJ, Rhind SM, Will RG, Woolhouse ME. Comparative evidence for a link
between Peyer's patch development and susceptibility to transmissible spongiform encephalopathies. BMC Infect Dis 2006; 6: 5.


2005


Murray KL.  Vertical transmission of variant CJD. JNNP 2005; 76(9): 1318.


2003


2002


368. Green AJE, Ramljak S, Muller WEG, Knight RSG, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using a highly sensitive 14-3-3 protein capture assay. Neurosci Lett 2002; 324:57-60.

369. Green AJE, Ramljak S, Muller WEG, Knight RSG, Schroder HC. 14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein. Neurosci Lett 2002; 324:57-60.


2001


441. Will RG. The facts about vCJD. The Practitioner 2001; 245:469.


2000


1999


Ironside JW. The work of the National CJD Surveillance Unit. ACP News 1998; 27-29.


1997


1996


1995


640. Will RG. Epidemiology of CJD in the UK. Medien in der Medizin 1995;11.


1994


1993


1992


1991


692. Will RG. Is there a potential risk of transmission of BSE to the human population and how may this be assessed? In: Bradley R, Savey M, Marchant B,


1990


